Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Akari Therapeutics ( (AKTX) ).
On October 22, 2025, Akari Therapeutics appointed Kameel Farag as interim Chief Financial Officer, succeeding Torsten Hombeck. Farag, with a robust background in biotechnology and finance, has been involved in significant growth and financial operations at companies like Aspen Neuroscience and Amgen Inc. His appointment is accompanied by a Consulting Agreement that outlines his compensation and potential incentives related to capital raises, highlighting the company’s strategic focus on financial management and growth.
The most recent analyst rating on (AKTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.
Spark’s Take on AKTX Stock
According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral.
Akari Therapeutics’ stock score of 44 reflects significant challenges due to its current financial instability and lack of revenue. While the technical analysis indicates a neutral trend, the company’s speculative nature due to the absence of traditional valuation metrics underscores the risk. However, the recent positive corporate event with the appointment of a new CEO brings some potential for strategic improvement, slightly offsetting the otherwise high-risk profile.
To see Spark’s full report on AKTX stock, click here.
More about Akari Therapeutics
Akari Therapeutics is a company operating in the biotechnology industry, focusing on developing treatments for rare and orphan diseases.
Average Trading Volume: 201,831
Technical Sentiment Signal: Sell
Current Market Cap: $24.55M
For a thorough assessment of AKTX stock, go to TipRanks’ Stock Analysis page.